chevron_leftBack
As of 13 June 2026, Vicapsys Life Sciences, Inc. has a market cap of $47.26M USD, ranking #30977 globally and #4493 in the United States.
It ranks #2797 in the Healthcare sector, and #542 in the Biotechnology industry.
Key Stats
Market Cap
$47.26MUSD
Enterprise Value
$47.75MUSD
Net Income (TTM)
-$1.35MUSD
PB Ratio
-17.9
Company Profile
Country (HQ)
Sector
Healthcare
Industry
Biotechnology
CEO
Federico Pier
open_in_new
Employees
2
Founded
1997
Website
vicapsys.com
open_in_new
warningChart data may be delayed
| 1d | 1w | 1m | 3m | 6m | 1y |
|---|---|---|---|---|---|
| 47% | 873% | -2.7% | -2.7% | -18% | -18% |
News
Loading...
Markets
| Exchange | Ticker | Price |
|---|---|---|
|
VICP
Vicapsys Life Sciences Inc
ISIN: US92560A1060
Shares Out.:
Shares Outstanding:
32.371M1
Shares Float:
18.414M2
TV:
TradingView:
SA:
Stock Analysis:
YF:
Yahoo Finance:
GF:
Google Finance:
BA:
Barron's:
MS:
Morningstar:
|
1.46 USD |
1Market cap is calculated using shares outstanding.
2Float shares are publicly tradable shares, excluding insider-held stock.
About Vicapsys Life Sciences, Inc.
Vicapsys Life Sciences, Inc. focuses on the development and commercialization of VICAPSYN, a proprietary product. The company’s product is applied to transplantation therapies and related stem-cell applications in the transplantation field. It also develops VYBRIN, a product based on CXCL12 for prevention of post-surgical adhesions in abdominal surgery, coating of implantable medical devices and other implants to eliminate fibrosis, and wound healing with a focus on diabetic ulcers. The company was formerly known as Phage Therapeutics International, Inc. and changed its name to Vicapsys Life Sciences, Inc. in September 2017. Vicapsys Life Sciences, Inc. was incorporated in 1997 and is based in Suwanee, Georgia.
Similar Companies
| Name |
Market Cap (USD)
diff.
|
PE | Country |
|---|---|---|---|
NASDAQ: AMGN
|
$182.42B
386K%
|
23.9
|
|
NASDAQ: GILD
|
$159.92B
338K%
|
19.0
|
|
NASDAQ: NTRA
|
$27.6B
58K%
|
-
|
|
NYSE: IQV
|
$26.3B
56K%
|
20.0
|
|
NASDAQ: UTHR
|
$25.03B
53K%
|
20.4
|
|
NASDAQ: MRNA
|
$18.13B
38K%
|
-
|
| Name |
Market Cap (USD)
diff.
|
PE | Country |
|---|---|---|---|
EBR: ARGX
|
$47.84B
101K%
41.39B EUR
|
39.9
|
|
KRX: 207940
|
$44.84B
95K%
68.19T KRW
|
35.5
|
|
ASX: CSL
|
$42.36B
90K%
60.27B AUD
|
29.3
|
|
SIX: LONN
|
$42.3B
89K%
33.71B CHF
|
37.2
|
|
KRX: 068270
|
$28.11B
59K%
42.76T KRW
|
43.8
|
|
NASDAQ: BNTX
|
$25.69B
54K%
|
-
|
chevron_leftBack